Weight Loss Management in Endometrial Cancer Survivors

Part of paid clinical trials in Kansas City, Kansas.

Sponsor
University of Kansas Medical Center
Study ID
NCT06877572
Status
Recruiting
Apply to this trial

Conditions

  • Early Stage Endometrial Cancer
  • Endometrial Cancer Survivors
  • Weight Management

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Weight loss with pharmacotherapy — BEHAVIORAL
    Patients will meet with a weight management specialist and discuss their options for weight loss including medications (GLP-1 agonist, naltrexone/bupropion, orlistat, or phentermine/topiramate) or bariatric surgery.
  • Weight loss without pharmacotherapy — BEHAVIORAL
    Participants not on medications will have their weight recorded at subsequent cancer surveillance or other routine medical visits

Study Details

This study is being done to understand how oncologists can engage a multidisciplinary team to help endometrial cancer survivors with obesity to engage in a weight management program and potentially start a weight loss medication. Obesity often impacts the future health and longevity of early-stage endometrial cancer survivors more than their cancer diagnosis. Patients will be referred to the KUMC OB/Gyn weight management clinic to discuss weight management options. * If patients decide to use medications for weight loss, then the study will collect data from their chart that is recorded as part of routine monitoring for patients on weight loss medications. * If patients decide not to use any medications, the study will monitor physical exam and lab data collected as part of their routine medical care. The study will also try to understand reasons why patients did or did not start using a weight loss medication.

Key Dates

Start date
Mar 25, 2025
Status verified
Oct 2025
Primary completion
Oct 31, 2028
Completion
Oct 31, 2030

Study Design

Enrollment
50 participants (estimated)

Arms

  • Arm: Endometrial cancer survivors with weight management
    Survivors of low-risk early-stage endometrial cancer up to 36 months post primary treatment with body mass index (BMI) ≥30 kg/m2

Primary Outcome Measure

Percentage of participants referred to weight loss clinic who are able to start weight management medications [ Time Frame: 12 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Kansas Medical CenterKansas CityKansas66160
Principal Investigator
[email protected]
913-588-0885
Melissa Javellana, MD (PRINCIPAL_INVESTIGATOR)
Yasmin Abedin, MD (SUB_INVESTIGATOR)
Ian Cook, MD (SUB_INVESTIGATOR)
Johanna Finkle, MD (SUB_INVESTIGATOR)
Andrea Jewell, MD (SUB_INVESTIGATOR)
Lori Spoozak, MD (SUB_INVESTIGATOR)
Rana Aliani, MD (SUB_INVESTIGATOR)
Thomas Chavez, MD (SUB_INVESTIGATOR)

Find similar trials in Kansas City, KS

By research site
University of Kansas Medical Center· Kansas City, KS

Related Studies